At last!29 Jul 2021 08:06
Professor Lindy Durrant, Chief Executive Officer, Scancell, commented:"We are very pleased that this CTA was approved so rapidly, reflecting the importance of the study in South Africa, and it is a testament to the dedication and professionalism of the Scancell team and our colleagues in Cape Town. Our approach of targeting the conserved N protein in addition to generating potent, cross-reactive VNAbs has the potential to provide a significant clinical advantage by eliciting potent T cells that can destroy cells infected with any SARS-CoV-2 variants and other SARS-CoV viruses that may emerge in the future."
Now it should be interesting....